Compare DSX & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSX | FENC |
|---|---|---|
| Founded | 1999 | 1996 |
| Country | Greece | United States |
| Employees | N/A | 35 |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.1M | 350.0M |
| IPO Year | 2005 | 2010 |
| Metric | DSX | FENC |
|---|---|---|
| Price | $2.51 | $10.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | ★ 998.3K | 115.7K |
| Earning Date | 11-19-2026 | 11-12-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | $13.33 | $62.55 |
| Revenue Next Year | $8.68 | $42.10 |
| P/E Ratio | ★ $16.02 | $166.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.60 | $5.65 |
| 52 Week High | $3.20 | $13.25 |
| Indicator | DSX | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 33.16 | 44.22 |
| Support Level | $2.27 | $9.87 |
| Resistance Level | $2.61 | $10.66 |
| Average True Range (ATR) | 0.10 | 0.48 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 10.64 | 36.36 |
Diana Shipping Inc provides shipping transportation services. The company, through its subsidiaries, operates a fleet of vessels consisting of dry bulk carriers such as Panamax, Kamsarmax, Post-Panamax, Capesize, and Newcastlemax vessels. Using this fleet, the firm provides transportation services for various goods, including coal, iron ore, and grains. It also transports minor bulks, including steel products, cement, and fertilizers, through its dry bulk carrier vessels. The operation of the vessels is the main source of revenue generation; the services provided by the vessels are similar, and all operate under the same economic environment.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.